EpCAM-targeted induction of apoptosis
Edwin Bremer1, Wijnand Helfrich
1Groningen University Institute for Drug Exploration, Department of Pathology and Laboratory Medicine, Section Medical Biology, Laboratory for Tumor Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Summary
EpCAM-targeted therapies, including bispecific antibodies and TRAIL fusion proteins, offer new strategies to induce apoptosis in cancer cells. These approaches aim to overcome immune evasion and apoptosis resistance, tipping the balance toward cancer cell death.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- EpCAM (Epithelial cell adhesion molecule) is a pancarcinoma target antigen utilized in various cancer therapies.
- Cancer cells evade immune detection via mechanisms like reduced MHCI expression and immune cell elimination.
- Resistance to apoptosis is a hallmark of cancer, often essential for tumor cell survival.
Purpose of the Study:
- To review and discuss therapeutic strategies targeting EpCAM for apoptosis induction in cancer.
- To explore the potential of EpCAM-selective bispecific antibodies and TRAIL fusion proteins.
- To highlight approaches that overcome cancer immune evasion and apoptosis resistance.
Main Methods:
- Review of existing literature on EpCAM-targeted therapies.
- Analysis of immune effector mechanisms and apoptosis pathways in cancer.
- Discussion of bispecific antibodies and TRAIL fusion proteins as therapeutic modalities.
Main Results:
- EpCAM-targeted strategies can selectively reactivate immune effector cells or molecules.
- Bispecific antibodies and TRAIL fusion proteins show promise in inducing apoptosis.
- These therapies can overcome cancer cell immune evasion and apoptosis resistance.
Conclusions:
- EpCAM-targeted bispecific antibodies and TRAIL fusion proteins represent promising avenues for cancer treatment.
- These approaches can selectively induce apoptosis in cancer cells by overcoming resistance mechanisms.
- Further research into these targeted therapies holds significant potential for improving cancer patient outcomes.
Related Concept Videos
01:22Cellular Injury V: Apoptosis and Autophagy
Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
01:30Apoptosis
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size reduction of the tissue.
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:24Caspases
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
01:17Phagocytosis of Apoptotic Cells
Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or immature dendritic cells. Non-professional phagocytes such as epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes.
Normal cells contain receptors that prevent them from being recognized by phagocytes.
Normal cells contain receptors that prevent them from being recognized by phagocytes.